A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity. By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.
A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity.
By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity. By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.
Open the app view to save this story, compare related coverage, and continue from the same source.